proteasomal

Valproic Acid (2-Propylpentanoic Acid) 是一种 HDAC 抑制剂，可抑制 HDAC1 活性，诱导 HDAC2 降解，具有口服活性。Valproic Acid 可以用于癫痫和躁郁症的研究。

Valproic acid sodium salt (Sodium Valproate) 是一种HDAC 抑制剂，可抑制HDAC1的活性，诱导HDAC2的降解。它激活Notch1信号并抑制小细胞肺癌细胞的增殖。它可研究癫痫、偏头痛和双相情感障碍等。

Divalproex Sodium (Valproate semisodium) 结合并抑制 γ-氨基丁酸 (GABA) 转氨酶，其抗惊厥活性可通过增加 GABA 脑浓度和抑制分解 GABA 或阻止 GABA 再摄取到神经胶质和神经末梢的酶来发挥。它也是一种 HDAC 抑制剂。由丙戊酸钠和丙戊酸组成，具有抗惊厥和抗癫痫活性。 Divalproex 还可以通过抑制电压敏感的钠通道来抑制重复的神经元放电。

Obatoclax Mesylate (GX15-070) 是泛 BCL-2家族蛋白抑制剂，对 BCL-2 的 Ki 值为 220 nM。它是 BH3 模拟物，具有抗癌和广谱抗寄生虫活性。它诱导自噬依赖性细胞死亡，并靶向细胞周期蛋白 D1 进行蛋白酶体降解。

(E)-Ferulic acid ((E)-Coniferic acid) 是阿魏酸的异构体，阿魏酸是在植物细胞壁中丰富存在的芳香族天然产物。 它引起 β-catenin 的磷酸化，导致其蛋白酶体降解，增加促凋亡因子 Bax 的表达，降低促生存因子的表达。它在人肺癌细胞系 H1299 中发挥抗增殖和抗迁移作用。

Nrf2 degrader 30是一种小分子PROTAC，能够抑制Nrf2的降解，从而增强Nrf2的活性。Nrf2（Nuclear factor erythroid 2-related factor 2）是一种关键的转录因子，调控细胞抗氧化反应和多种细胞保护机制。Nrf2的活性主要通过其与Keap1的相互作用来调节，Keap1作为E3泛素连接酶复合体的适配器，促进Nrf2的泛素化和蛋白酶体降解。

BP is a rare class enhancer of proteasomal activation in the absence of a heat shock response.

Corosolic acid (Colosic acid) 是从大花紫薇中提取的一种天然产物，具有抗肿瘤活性。

CP5V, a PROTAC, induces mitotic inhibition, and suppresses cancer cell proliferation. It specifically degrades Cdc20 by linking Cdc20 to the VHL VBC complex for ubiquitination followed by proteasomal degradation.

JH-XI-10-02 causes proteasomal degradation, does not affect CDK8 mRNA levels. JH-XI-10-02 shows no effect on CDK19. JH-XI-10-02 is a potent and selective degrader of CDK8, with an IC50 of 159 nM, based on PROTAC.

PR-924 is a selective inhibitor of tripeptide epoxyketone immunoproteasome subunit LMP-7 (IC50: 22 nM). PR-924 inhibits growth and triggers apoptosis in multiple myeloma (MM) cells. PR-924 has antitumor activities. PR-924 covalently modifies proteasomal N-terminal threonine active sites.

ES-072是一种口服选择性EGFR突变体(EGFR-T790M)抑制剂，主要通过抑制EGFR-T790M活性并激活GSK3α工作。通过这一途径，该化合物使PD-L1在Ser279和Ser283位点发生磷酸化，进一步促进E3泛素连接酶ARIH1对PD-L1的招募，从而标记其进行泛素化和蛋白酶体介导的降解。此作用机制既抑制了癌细胞生长，也通过降低PD-L1水平来加强抗肿瘤免疫响应。因此，ES-072对于抑制非小细胞肺癌细胞(NSCLC)的增殖具有显著效果。

JBJ-08-178-01 作为一种选择性酪氨酸激酶抑制剂，特异性地针对人表皮生长因子受体2 (HER2) 的突变形态，表现出显著的抗肿瘤活性。该化合物通过促进肺癌中HER2受体的蛋白酶体降解，有效降低其激酶活性及蛋白表达量。在非小细胞肺癌治疗的研究中，JBJ-08-178-01 显示出了积极的治疗潜力。

Immunoproteasome activator 1 (compound A) 作为一种高选择性的免疫蛋白酶体激活剂，能显著地促进MHC-I结合肽的呈递，增幅达到超过100倍。该化合物通过与蛋白酶体的结构亚单位PSMA1结合，并进一步促使蛋白酶体激活物PA28α β (PSME1 PSME2) 与免疫蛋白酶体的有效结合，从而发挥其作用。

CQ627 是一种靶向降解 RIOK2 的分子胶 (Molecular Glues)。CQ627 通过招募 E3 泛素连接酶 RNF126，在 MOLT4 白血病细胞系中通过泛素-蛋白酶体系统 (UPS) 有效降解 RIOK2，其 DC50 值为 410 nM。它能剂量依赖性地诱导 MOLT4 细胞系的凋亡 (Apoptosis)，阻止其细胞周期于 G2 M 阶段，并在多种癌症细胞系中表现出抗增殖活性。此外，CQ627 在 MOLT4 异种移植小鼠模型中也显示了体内抗癌效果。

10-SLF 是一种 PROTAC FKBP12 降解剂，通过诱导 FKBP12 和 FBXW7-R465C 之间的三元复合物形成，促进 FBXW7-R465C 依赖的 FKBP12 蛋白酶体降解。此外，10-SLF 还能选择性降低在表达 FBXW7-R465C 的细胞中的 FKBP12 水平。

CEP-1612 is a proteasomal inhibitor responsible for the proteolysis of proteins that regulate important cell cycles and apoptosis. CEP-1612 can induce p21WAF1 and p27KIP1 expression and apoptosis, and inhibit tumor growth of human lung cancer.

Promotes proteasomal degradation of Miro1 (mitochondrial Rho GTPase 1). Reduces Miro1 levels in fibroblasts from Parkinson's disease (PD) patients (IC50 = 7.8 μM). Exhibits no significant effect on related outer mitochondrial membrane protein Mitofusin. Reduces stress-induced degeneration of dopaminergic neurons derived from PD patient iPSCs. Rescues age-dependent neuronal loss and prolongs lifespan in fly PD models.

Gliotoxin-13C13is intended for use as an internal standard for the quantification of gliotoxin by GC- or LC-MS. Gliotoxin is an immunosuppressive mycotoxin produced by pathogenic strains ofAspergillusand other fungi with diverse biological activities.1,2,3,4,5,6,7,8It inhibits 20S proteasomal chymotrypsin activity (IC50= 10 μM), blocking the degradation of IκBα and preventing the activation of NF-κB.2,3Gliotoxin induces apoptosis in monocytes and dendritic cells and reduces phagocytosis by neutrophils.4,5It suppresses viral infection by Nipah and Hendra virus in HEK293T cells (IC50s = 149 and 579 nM, respectively).6Under reducing conditions, gliotoxin inhibits leukotriene A4hydrolase epoxide hydrolase activity, but not aminopeptidase activity, and leukotriene B4synthesis in neutrophils and monocytes.7

NCT02 是一种细胞周期蛋白 K 降解剂，可诱导细胞周期蛋白 K (CCNK) 的泛素化和 CCNK 及其复合物 CDK12 的蛋白酶体降解。NCT02具有研究转移性结直肠癌 (CRC) 的潜力。

MMRi62 (7-[(2,3-dichlorophenyl)-(pyridin-2-ylamino)methyl]quinolin-8-ol) 是一种铁死亡 (ferroptosis) 诱导剂，靶向 MDM2-MDM4 (抑癌基因 p53 负调控因子)。MMRi62 对胰腺导管腺癌 (PDAC) 细胞显示出 p53 独立的促凋亡 (apoptosis) 活性，并诱导其自噬 (autophagy)。MMRi62 诱导铁死亡，伴随着活性氧增加和铁蛋白重链 (FTH1) 溶酶体降解。MMRi62 还可导致突变型 p53 的蛋白酶体降解，并对具有 KRAS 和 TP53 高频突变特征的原位异种移植 PDAC 小鼠模型具有体内药效。

3-Deazaneplanocin A (DZNep) 是一种组蛋白甲基转移酶 (EZH2) 和 S-腺苷同型半胱氨酸水解酶 (AHCY) 双重抑制剂，具有抗正痘活性，可在动物模型中能够诱导其靶标的蛋白酶体降解并降低毒性，抑制肝脏、肾脏、腹膜和气道的纤维化。

BIIB028 is a small-molecule inhibitor of heat shock protein (Hsp) 90 with potential antineoplastic activity. Hsp90 inhibitor BIIB028 blocks the binding of oncogenic client proteins to Hsp90, which may result in the proteasomal degradation of these proteins and so the inhibition of tumor cell proliferation. Hsp90 is a molecular chaperone that plays a key role in the conformational maturation of oncogenic signaling proteins, such as Her2 Erbb2, Akt, Raf1, Bcr-Abl, and mutated p53, in addition to other molecules involved in cell cycle regulation and immune responses.

Luminespib, also known as AUY-922, NVP-AUY922, VER52296, is a derivative of 4,5-diarylisoxazole and a third-generation heat shock protein 90 (Hsp90) inhibitor with potential antineoplastic activity. Hsp90 inhibitor AUY922 has been shown to bind with high affinity to and inhibit Hsp90, resulting in the proteasomal degradation of oncogenic client proteins; the inhibition of cell proliferation; and the elevation of heat shock protein 72 (Hsp72) in a wide range of human tumor cell lines.